The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced solid tumors. The FDA has cleared the investigational new drug (IND) ...
A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...
− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback